Expressions and prognostic significance of PTEN and PD-1 protein in patients with classical Hodgkin's lymphoma.
10.3760/cma.j.issn.0253-2727.2018.10.010
- Author:
Bing XIA
1
,
2
,
3
;
Dong Wei WU
;
Teng Teng WANG
;
Shan Qi GUO
;
Yi WANG
;
Hong Liang YANG
;
Wen XU
;
Chen TIAN
;
Lian Yu ZHANG
;
Bao Cun SUN
;
E M SOTOMAYOR
;
Yi Zhuo ZHANG
1
,
2
,
3
Author Information
1. Department of hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer
2. Key Laboratory of Cancer Prevention and Therapy, Tianjin
3. Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China.
- Publication Type:Journal Article
- Keywords:
Hodgkin lymphoma;
PTEN phosphohydrolase;
Prognosis;
Programmed cell death 1 receptor
- MeSH:
Adolescent;
Adult;
Aged;
Child;
Female;
Hodgkin Disease;
Humans;
Male;
Middle Aged;
PTEN Phosphohydrolase/analysis*;
Prognosis;
Programmed Cell Death 1 Receptor/analysis*;
Retrospective Studies;
Young Adult
- From:
Chinese Journal of Hematology
2018;39(10):839-844
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To elucidate the expression levels of key immune biomarkers, phosphate and tension homology deleted on chromosome ten (PTEN) and programmed cell death protein1(PD-1),of different immune tolerance pathway in classic Hodgkin's lymphoma (CHL) to further determine their clinical role and prognostic significance. Methods: The clinical features and prognostic factors of 56 CHL patients, who were admitted to the TianJin Medical University Cancer Institute from February 2003 to August 2013, were retrospectively analyzed. PTEN and PD-1 protein expression levels were analyzed by immunohistochemistry, Epstein-Barr virus encoded RNA (EBER) was performed by in situ hybridization assay. Correlations between the expression of biomarkers and clinicopathologic parameters were examined and survival analyses were performed. Results: This cohort of 56 CHL patients included 34 males and 22 females with a median age of 25 years (ranged from 7 to 71 years). In a univariate analysis, age≥45, IPS score >2, EBER positive, high expression of PTEN protein conferred inferior 5-year OS and 5-year PFS; In a multivariate model, age≥45, IPS score >2, EBER positive, high expression of PTEN protein were identified as the independent adverse prognostic factors for CHL. Conclusions: This study suggested for the first time that PTEN was independent prognostic immune biomarkers in CHL, which provided the novel therapeutic strategy of immune therapy for CHL.
